Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty - FACT


The FACT was a prospective multicenter, double-blind, randomized trial designed to evaluate whether treatment with nadroparin, a low-molecular-weight heparin, started 3 days before coronary angioplasty and continued for 3 months, affects angiographic restenosis or clinical outcomes.